What, When, and How of Biomarker Testing in Non–Small Cell Lung Cancer

Author: Gregory L. Riely MD 1
View More View Less
  • 1 Presented by Gregory L. Riely, MD, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Restricted access

Biomarker testing is recommended for all patients diagnosed with non–small cell lung cancer. At a minimum, testing should include the mutations/fusions EGFR, ALK, ROS1, and the protein programmed death ligand-1 (PD-L1), because FDA-approved therapies are available for these alterations. Other actionable molecular findings include RET rearrangements, BRAFV600E mutations, and MET exon 14 alterations. If adequate testing was not performed at treatment initiation, molecular testing should be performed before administration of subsequent lines of therapy. In patients with EGFR-mutant lung cancer, when resistance develops, physicians should seek to identify the T790M mutation using plasma and tissue assays, because osimertinib therapy is available for this mutation.

Correspondence: Gregory L. Riely, MD, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065. E-mail: rielyg@mskcc.org
  • 1.

    Reck M, Rodriguez-Abreu D, Robinson AG. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:18231833.

    • Search Google Scholar
    • Export Citation
  • 2.

    Rimm DL, Han G, Taube JM. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer [published online ahead of print March 9, 2017]. JAMA Oncol, doi: 10.1001/jamaoncol.2017.0013.

    • Search Google Scholar
    • Export Citation
  • 3.

    Rosell R, Moran T, Queralt C. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958967.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 4300 1402 151
PDF Downloads 916 315 50
EPUB Downloads 0 0 0